Gleason Score News and Research

RSS

NYU Langone hits milestone with its 1,000th focal cryotherapy procedure

Just two days after his minimally invasive prostate cancer treatment at NYU Langone Health, Broadway performer André De Shields, 80, was back onstage preparing for his next show, Cats: The Jellicle Ball, which debuted in April 2026.

5 Jun 2026

Metabolic reprogramming drives prostate cancer progression and treatment resistance

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy (ADT), the disease often progresses to castration-resistant prostate cancer (CRPC).

24 Jan 2026

RAB26 identified as a critical regulator of prostate cancer aggressiveness

Prostate cancer (PCa) is one of the most common malignant tumors in men worldwide. While early detection has improved patient outcomes, effective therapies for advanced disease remain limited.

11 Sep 2025

Guideline-based prostate cancer treatment helps most men outlive the disease

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer.

14 Jul 2025

Study confirms high survival rates for men with low-risk prostate cancer

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 90% were likely to survive their cancer for their remaining life-expectancy.

11 Jul 2025

Genetic test outperforms PSA and MRI in spotting deadly prostate cancer early

A UK study found that using a polygenic risk score to identify men at highest genetic risk of prostate cancer significantly improved detection of clinically important disease. This approach caught aggressive cancers that standard PSA and MRI screening would have missed.

10 Apr 2025

Patient-centered reports help reduce worry and improve understanding of test results

In April 2021, a provision in the 21st Century Cures act took effect which required that all medical test results be released to a patient's electronic medical record as soon as they become available.

3 Jan 2025

Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer

A recent European Urology Oncology study assessed the mortality risks, based on the Gleason score and clinical parameters, in patients with prostate cancer.

11 Jul 2024

Revolutionizing prostate cancer diagnostics with 3D pathology and deep learning

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States.

11 Mar 2024

Genomic testing rates soar for Black patients with prostate cancer after introduction of precision medicine navigators

The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.

3 Oct 2023

Predicting bone metastases type in prostate cancer using MRI

Researchers investigated the differences in prostate MRI findings and clinical characteristics between patients with prostate cancer exhibiting bone metastases.

20 Jul 2023

What is the relative burden of oncologic and nononcologic mortality among long-term survivors of cancer in the US?

In a recent study, researchers estimated mortality risk for long-term survivors of cancer.

17 Jul 2023

Enhanced prediction of prostate cancer recurrence using machine learning model

Predicting the course of prostate cancer is challenging because only a fraction of prostate cancer patients experience recurrence after radical prostatectomy or radiation therapy.

14 Feb 2023

Clinical trial confirms the safety, efficacy of shortened radiation therapy for high-risk prostate cancer patients

A new randomized study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy.

24 Oct 2022

New model predicts which patients will gain most from PSMA PET scan

A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.

16 Feb 2021

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

11 Feb 2021

Genetic alterations linked to high incidence of prostate cancer in African American men

Prostate cancer tumors from African American men had higher frequencies of certain genetic alterations that may be associated with aggressive disease, compared with prostate cancer tumors from white men.

28 Oct 2020

New eco-evolutionary mathematical model can predict prostate cancer aggressiveness

Prostate cancer is the most common cancer in men. One in nine men will be diagnosed during their lifetime. While most men will not die from prostate cancer, there is a small subset of patients whose disease is so aggressive at the time of diagnosis that surgery and radiation are not able to control their cancer.

14 May 2020

Study demonstrates accuracy of AI system in diagnosing prostate cancer

The Lancet Oncology has today published the results of a study demonstrating the accuracy of an artificial intelligence system in diagnosing prostate cancer in tissue samples.

10 Jan 2020

New AI system determines aggressiveness of prostate cancer better than most pathologists

Researchers at Radboud university medical center have developed a 'deep learning' system that is better than most pathologists at determining the aggressiveness of prostate cancer. The AI system, which uses tissue samples to arrive at its diagnosis, taught itself to identify prostate cancer based on data from over 1200 patients.

9 Jan 2020